Hormonal
Higher baseline expression of caveolin-1 in adipocytes enables greater hypertrophic expansion (fat cell enlargement) in response to caloric overfeeding in healthy humans.
Your body's ability to store fat in your cells (hypertrophy) when you eat more is linked to the levels of a protein called caveolin-1. People with higher levels of this protein tend to get larger fat cells rather than creating new ones. While you cannot directly 'take' caveolin-1, understanding that fat cells are dynamic and responsive to lipid levels (shrinking when mobilized) suggests that metabolic flexibility is key.
In subjects responding to overfeeding by adipocyte enlargement, we found that caveolin-1 protein expression at baseline positively correlated with the change in fat cell size (Fig. 4D), whereas no association was observed in hyperplastic responders.
Why this rating
Combines in vitro/in vivo mechanistic data with a human clinical trial (n=35), though the human sample is small and observational regarding baseline levels.
Source
Caveolin-1 Expression and Cavin Stability Regulate Caveolae Dynamics in Adipocyte Lipid Store Fluctuation
Nolwenn Briand et al. · Diabetes · 2014
DOI 10.2337/db13-1961
More from this paper
- Overexpression of caveolin-1 in adipocytes increases caveolae density, enhances insulin-stimulated glucose uptake, and allows for larger lipid droplet storage.Strong
- Sustained lipid mobilization (fat loss) leads to the disassembly of caveolae through the degradation of cavin proteins (cavin-1, cavin-2, EHD2), reducing caveolae density.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →